Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Debt to Equity (2016 - 2017)

Historic Debt to Equity for Corcept Therapeutics (CORT) over the last 2 years, with Q2 2017 value amounting to $0.07.

  • Corcept Therapeutics' Debt to Equity fell 9204.51% to $0.07 in Q2 2017 from the same period last year, while for Jun 2017 it was $0.07, marking a year-over-year decrease of 9204.51%. This contributed to the annual value of $0.35 for FY2016, which is N/A changed from last year.
  • Per Corcept Therapeutics' latest filing, its Debt to Equity stood at $0.07 for Q2 2017, which was down 9204.51% from $0.2 recorded in Q1 2017.
  • Corcept Therapeutics' Debt to Equity's 5-year high stood at $1.24 during Q1 2016, with a 5-year trough of $0.07 in Q2 2017.